PRH1
Salivary acidic proline-rich phosphoprotein 1/2
Also known as: Pr, PRH2, PRPC_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P02810
- Gene
- PRH1
- Ensembl
- ENSG00000134551
- Chromosome
- 12
- Canonical length
- 166 aa
- Protein class
- Predicted secreted proteins
- Secretome location
- Secreted to digestive system
OverviewNCBI Gene
This gene encodes a member of the heterogeneous family of proline-rich salivary glycoproteins. The encoded preproprotein undergoes proteolytic processing to generate one or more mature isoforms before secretion from the parotid and submandibular/sublingual glands. In western population this locus is commonly biallelic and encodes proline-rich protein (PRP) isoforms, PRP-1 and PRP-2. The reference genome encodes the PRP-1 allele. Certain alleles of this gene are associated with susceptibility to dental caries. This gene is located in a cluster of closely related salivary proline-rich proteins on chromosome 12. [provided by RefSeq, Oct 2015]
Canonical amino-acid sequenceUniProt
166 residues, UniProt reviewed canonical sequence.
>P02810|PRH1
1 MLLILLSVAL LAFSSAQDLD EDVSQEDVPL VISDGGDSEQ FIDEERQGPP LGGQQSQPSA
61 GDGNQNDGPQ QGPPQQGGQQ QQGPPPPQGK PQGPPQQGGH PPPPQGRPQG PPQQGGHPRP
121 PRGRPQGPPQ QGGHQQGPPP PPPGKPQGPP PQGGRPQGPP QGQSPQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PRH1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.72
- Highest tissue expression
- 21,602 nTPM
Expression across tissuesHPA
Tissue
- salivary gland: 21,602 nTPM
- pancreas: 24 nTPM
- esophagus: 17 nTPM
- heart muscle: 4.3 nTPM
- lung: 4.3 nTPM
- testis: 3.6 nTPM
Single-cell type
- salivary acinar cells: 7,506 nCPM
- salivary myoepithelial cells: 1,648 nCPM
- neutrophils: 258 nCPM
- innate lymphoid cells: 68 nCPM
- salivary basal cells: 62 nCPM
- salivary duct cells: 59 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- white matter: 7.7 nTPM
- medulla oblongata: 6.7 nTPM
- pons: 6.6 nTPM
- cerebellum: 6.1 nTPM
- cerebral cortex: 6 nTPM
- basal ganglia: 5.8 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PRH1.
Disease | AutoantibodyPubMed
Conditions in which antibodies against PRH1 are reported. Each links to that disease's full target list.
Showing 3 of 5 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for PRH1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
20 publications
- Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies.
1996 · Thromb Haemost · RCR 5.1 · 131 citations - The thrombotic diathesis associated with the presence of phospholipid antibodies may be due to low levels of free protein S.
1992 · Am J Med · RCR 3.1 · 67 citations - Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome.
2014 · J Thromb Haemost · RCR 2.4 · 59 citations - Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases.
2007 · Arthritis Rheum · RCR 1.5 · 48 citations - Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system.
1998 · Clin Exp Immunol · RCR 1.4 · 43 citations
Show 15 more
- Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C.
2008 · Blood Coagul Fibrinolysis · RCR 1 · 34 citations - pANCA, ASCA, and OmpC antibodies in patients with ankylosing spondylitis without inflammatory bowel disease.
2010 · J Rheumatol · RCR 0.9 · 32 citations - Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?
2021 · Rheumatology (Oxford) · RCR 0.9 · 12 citations - Thrombosis and occlusion of vascular access in hemodialyzed patients.
2011 · Semin Thromb Hemost · RCR 0.8 · 19 citations - In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis.
2005 · Kidney Int · RCR 0.8 · 21 citations - Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients.
2002 · Thromb Haemost · RCR 0.6 · 21 citations - Levels of antibodies against protein C and protein S in pregnancy and in preeclampsia.
2009 · J Matern Fetal Neonatal Med · RCR 0.4 · 14 citations - Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus.
2009 · Thromb Res · RCR 0.3 · 11 citations - Anti-human protein S antibody induces tissue factor expression through a direct interaction with platelet phosphofructokinase.
2014 · Thromb Res · RCR 0.3 · 7 citations - Low levels of activated protein C in patients with systemic lupus erythematosus do not relate to lupus anticoagulants but to low levels of factor II.
2002 · Br J Haematol · RCR 0.2 · 8 citations - [A childhood case of antiphospholipid syndrome].
2009 · J Mal Vasc · RCR 0.1 · 2 citations - [Advanced clinical laboratory studies in the graduate school of medicine--studies on pathogenic mechanisms of anti-phospholipid syndrome].
2009 · Rinsho Byori · RCR 0.1 · 2 citations - Evaluation of anti-activated protein C antibody development in patients with severe sepsis from four clinical studies with drotrecogin alpha (activated).
2009 · J Thromb Haemost · RCR 0.1 · 2 citations - Human thrombin variable region 1, including E39, is involved in interactions with alpha 1-antitrypsin M358R and protein C.
1995 · FEBS Lett · RCR 0 · 1 citations - Prevalence and prognostic value of activated protein C resistance and anti-protein C antibodies in patients with aPLs: an APS ACTION Registry study.
2026 · Rheumatology (Oxford)
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.36
- gnomAD pLI
- 0.01
- gnomAD missense Z
- 0.69
- DepMap mean gene effect
- 0.12
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PRH1 as an antibody target. Whether an autoantibody or antibody against PRH1 could matter depends on whether native PRH1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PRH1 is annotated as secreted, so native PRH1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label PRH1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...